Report

SPHS: Details of Phase 3 Prostate Cancer Trial Based on Positive EMA Feedback...

Underlying
Sophiris Bio Inc

Sophiris Bio is a biopharmaceutical company focused on products for the treatment of urological diseases. Co. is developing topsalysin (PRX302) as a treatment for clinically significant localized prostate cancer and as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia, commonly referred to as an enlarged prostate. Topsalysin, a genetically modified recombinant protein, is delivered via ultrasound-guided injection directly into the prostate. This protein is selectively activated by enzymatically active prostate specific antigen, which is in the prostate, resulting in localized cell death and tissue disruption without damage to neighboring tissue and nerves.

Provider
Zacks
Zacks

​Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.

Other Reports on these Companies
Other Reports from Zacks

ResearchPool Subscriptions

Get the most out of your insights

Get in touch